Autoimmune Diseases

J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025

7 days ago talkbio0Tagged Autoimmune Diseases, Benefit, Biosimilars, drug price, formulary exclusion, Johnson & Johnson, manager, Pharmaceutical Services, Revenue Decline, Stelara, ustekinumab

Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease

Otsuka Inks $613M Deal for Cantargia’s Autoimmune Antibodies

7 days ago talkbio0Tagged Autoimmune Diseases, CAN10, Cantargia, global commercialization, Hidradenitis Suppurativa, IL1RAP antibodies, milestone payments, Otsuka Pharmaceutical, Systemic Scleroderma

Otsuka Pharmaceutical; Cantargia; autoimmune diseases; IL1RAP antibodies; CAN10; biotech deal; hidradenitis suppurativa; systemic sclerosis; milestone payments; global commercialization

Vor Bio’s $4B+ Revival Deal for RemeGen’s Autoimmune Drug Triggers Divergent Stock Moves

4 weeks ago talkbio0Tagged Autoimmune Diseases, CEO, Changing, Myasthenia Gravis, PIPE financing, RemeGen, Stock Reaction, Vor Bio

Vor Bio; RemeGen; telitacicept; autoimmune disease; $4 billion deal; myasthenia gravis; stock reaction; CEO change; PIPE financing

FDA Grants Dupixent (Dupilumab) Eighth Approval: Now Cleared for Bullous Pemphigoid

1 month ago talkbio0Tagged Approved, Autoimmune Diseases, Bullous pemphigoid, Drugs, Orphan, dupilumab, Dupixent, Priority Review, Regeneron, sanofi, type 2 inflammation, United States Food and Drug Administration

Dupixent; Dupilumab; Sanofi; Regeneron; bullous pemphigoid; FDA approval; type 2 inflammation; autoimmune disease; priority review; orphan drug

Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio

2 months ago talkbio0Tagged Autoimmune Diseases, biotech partnerships, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, bispecific, CD19xCD3, Clinical Development, CLN-978, Cullinan, Genrix Bio, Multiple Myeloma, T-Cell engager, velinotamig

Cullinan Therapeutics; Genrix Bio; BCMA bispecific; velinotamig; T-cell engager; autoimmune disease; CD19xCD3; CLN-978; multiple myeloma; clinical development; biotech partnerships

Kymera Soars on Early Protein Degrader Data

2 months ago talkbio0Tagged Autoimmune Diseases, Clinical Trials, KT-621, Kymera, Phase 1 (qualifier value), Protein Degradation, Metabolic, STAT6 degrader

Kymera Therapeutics; KT-621; STAT6 degrader; protein degradation; Phase 1 clinical trial; autoimmune disease

GlycoEra Raises $130M to Advance Protein Degraders Toward Clinic

2 months ago talkbio0Tagged Autoantibodies, Autoimmune Diseases, Clinical Trials, Funding, GE8820, GlycoEra, Holdings, Immunoglobulin IgG4, Precision Immunology, protein degraders

GlycoEra; protein degraders; $130 million funding; autoimmune diseases; GE8820; IgG4 autoantibodies; Novo Holdings; clinical trial; precision immunology

Kyverna Therapeutics Cuts 16% of Staff in Q1 2025 Amid Pipeline Focus

2 months ago talkbio0Tagged Autoimmune Diseases, CAR-T, KYV-101, Kyverna, layoffs, pipeline development, Staff

Kyverna Therapeutics; layoffs; biotech; staff reduction; Q1 2025; CAR-T; autoimmune diseases; pipeline development; KYV-101

FDA Approves Johnson & Johnson’s Imaavy: A New Treatment Option for Generalized Myasthenia Gravis

3 months ago talkbio0Tagged Approved, Autoimmune Diseases, Blocker, FCGRT gene, FcRn, Imaavy, immunoglobulin G, Myasthenia Gravis, Generalized, nipocalimab-aahu, United States Food and Drug Administration

Imaavy, nipocalimab-aahu, FcRn blocker, generalized myasthenia gravis (gMG), FDA approval, Johnson & Johnson, autoimmune disease, IgG reduction

Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions

3 months ago talkbio0Tagged Autoimmune Diseases, B cell immunomodulator program, biology (field), Flatulence, Nordisk alliance, OCT50, Programs - Publication Format

Autoimmune disease biotech, B cell immunomodulator program, OCT50 program, Novo Nordisk alliance, Winding down operations, Unresolved biology challenges